S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY

• F. Passamonti,
• J. Foran,
• A. Tandra,
• V. De Stefano,
• M. Laura Fox,
• A. Mattour,
• M. F. McMullin,
• A. C. Perkins,
• G. Rodriguez-Macías,
• H. Sibai,
• Q. Qin,
• J. Potluri,
• J. How

Affiliations

F. Passamonti

1 Department of Medicine and Surgery, University of Insubria, Varese, Italy

J. Foran

2 Mayo Clinic, Jacksonville, FL

A. Tandra

3 Indiana Blood and Marrow Transplant, Indianapolis, United States of America

V. De Stefano

4 Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University

M. Laura Fox

6 Department of Hematology, Hospital Universitari Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Hospital Campus, Barcelona, Spain

A. Mattour

7 Henry Ford Hospital, Detroit, MI, United States of America

M. F. McMullin

8 Centre for Medical Education, Queenʼs University Belfast, Belfast, United Kingdom

A. C. Perkins

9 Australian Centre for Blood Diseases, Monash University and The Alfred Hospital, Melbourne, Australia

G. Rodriguez-Macías

10 Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

H. Sibai

11 Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Q. Qin

12 AbbVie Inc, North Chicago, IL, United States of America

J. Potluri

12 AbbVie Inc, North Chicago, IL, United States of America

J. How

13 Division of Hematology, McGill University Health Center, Montreal, Canada